首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in the Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats after Oral Administration
【24h】

Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in the Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats after Oral Administration

机译:人参皂苷Rb1在肠道中的肠道通透性增加和抑制糖基化抑制作用对口服给药后糖尿病大鼠人参皂苷Rb1暴露的增强作用

获取原文
获取原文并翻译 | 示例
       

摘要

Panax ginseng is becoming a promising antidiabetic herbal medication. As the main active constituents of Panax ginseng, ginsenosides are well known, poorly absorbed chemicals. However, the pharmacokinetic behavior of ginsenosides under diabetic conditions is not fully understood. This study aimed to explore the alterations and potential mechanisms of pharmacokinetic behavior of ginsenoside Rb1 in diabetic rats compared with normal rats and rats fed a high-fat diet. Systemic exposure (area under the concentration-time curve extrapolated from zero to infinity) was significantly increased in diabetic rats after oral administration of Rb1. Oral bioavailability of Rb1 was significantly higher in diabetic rats (2.25%) compared with normal rats (0.90%) and rats fed a high-fat diet (0.78%). Further studies revealed that increased Rb1 exposure in diabetic rats may be mainly attributed to increased Rb1 absorption via the intestine and inhibited Rb1 deglycosylation by the intestinal microflora. Neither metabolic enzymes nor drug transporters displayed appreciable effects on Rb1 disposition. The transport of paracellular markers (fluorescein sodium and fluorescein isothiocyanate-dextran of 4 kDa) as well as Rb1 itself across the Caco-2 monolayer cultured with diabetic serum was promoted, demonstrating that increased paracellular permeability of the Caco-2 monolayer may benefit intestinal Rb1 absorption. In addition, Rb1 exposure was decreased in diabetic rats after Rb1 intravenous administration, which may result from increased Rb1 urinary excretion. In conclusion, Rb1 oral exposure was significantly increased under diabetic conditions, which is of positive significance to clinical treatment. The potential mechanism may be associated with the combined contribution of increased gut permeability and inhibited deglycosylation of ginsenoside Rb1 by intestinal microflora.
机译:人参正在成为一种有前途的抗糖尿病草药。人参皂苷是人参的主要活性成分,是众所周知的,吸收不良的化学物质。但是,人参皂甙在糖尿病条件下的药代动力学行为尚未完全了解。本研究旨在探讨人参皂苷Rb1在糖尿病大鼠中与正常大鼠和高脂饮食大鼠相比的变化及其潜在的药代动力学行为。口服Rb1后,糖尿病大鼠的全身暴露(浓度-时间曲线下从零到无限远的面积)显着增加。与正常大鼠(0.90%)和高脂饮食(0.78%)的大鼠相比,糖尿病大鼠(2.25%)的Rb1口服生物利用度显着更高。进一步的研究表明,糖尿病大鼠中Rb1暴露的增加可能主要归因于Rb1通过肠道的吸收增加以及肠道菌群抑制Rb1的去糖基化作用。代谢酶和药物转运蛋白均未显示出对Rb1处置的明显影响。促进了跨细胞标记物(4 kDa的荧光素钠和荧光素异硫氰酸荧光素-右旋糖酐)的转运以及Rb1自身在糖尿病血清培养的Caco-2单层上的转运,表明增加了Caco-2单层的细胞旁通透性可能有益于肠道Rb1吸收。此外,静脉注射Rb1后,糖尿病大鼠中Rb1的暴露减少,这可能是由于Rb1尿排泄增加所致。总之,在糖尿病条件下,Rb1口服暴露量显着增加,这对临床治疗具有积极意义。潜在的机制可能与肠道菌群增加肠道通透性和抑制人参皂苷Rb1的去糖基化的综合作用有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号